Rallybio Corporation (NASDAQ:RLYB) Receives $5.00 Average Price Target from Brokerages

Shares of Rallybio Corporation (NASDAQ:RLYB) have received a consensus rating of “Reduce” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $40.00.

Several equities analysts recently issued reports on RLYB shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a research report on Monday, December 29th. Wall Street Zen cut Rallybio from a “hold” rating to a “sell” rating in a research note on Sunday, October 12th.

Rallybio Stock Performance

NASDAQ:RLYB opened at $4.75 on Thursday. The firm has a market cap of $25.08 million, a P/E ratio of -1.86 and a beta of -1.05. Rallybio has a fifty-two week low of $1.76 and a fifty-two week high of $7.20. The firm has a 50-day simple moving average of $5.51 and a two-hundred day simple moving average of $4.95.

Rallybio (NASDAQ:RLYB) last issued its earnings results on Thursday, November 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.00) by $0.88. The firm had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.07 million. Rallybio had a negative net margin of 2,102.37% and a negative return on equity of 65.23%. On average, equities research analysts predict that Rallybio will post -1.34 EPS for the current year.

Hedge Funds Weigh In On Rallybio

An institutional investor recently raised its position in Rallybio stock. Citadel Advisors LLC grew its stake in shares of Rallybio Corporation (NASDAQ:RLYB) by 576.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 438,705 shares of the company’s stock after acquiring an additional 373,821 shares during the quarter. Citadel Advisors LLC owned about 1.04% of Rallybio worth $219,000 as of its most recent SEC filing. Institutional investors own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.